TENAX THERAPEUTICS, INC.
No SEC Form 4 filings for $TENX in the last 30 days.
See all $TENX insider activity →Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC reported beneficial ownership of 3,458,327 Tenax Therapeutics (TENX) securities, including 2,500,000 common shares and pre-funded warrants for 958,327 additional shares. Based on 37,423,917 shares outstanding as of July 28, 2026 plus warrant shares, the stake equals 9.0%. They report sole voting and dispositive power.
Biotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.
Tenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.
Over the past 7 days, alphai's AI scored 5 news stories mentioning TENX (TENAX THERAPEUTICS, INC.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 3 bearish.
Recent TENX coverage spans market movers, financial news and earnings.
This is a fresh ownership disclosure that can affect perceived control and potential financing or governance dynamics, but it does not provide operational or fundamental catalysts.
Phase 3 failure is a major de-risking event, likely driving sustained downside and option IV repricing.
Phase III miss materially increases probability of clinical and regulatory failure, pressuring valuation and near-term financing expectations.
Trial miss plus subgroup signals increases binary clinical-development risk and raises the probability of protocol redesign or new enrollment criteria.
Primary endpoint failure is a strong negative re-rating event for the development-stage biotech.
alphai scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC reported beneficial ownership of 3,458,327 Tenax Therapeutics (TENX) securities, including 2,500,000 common shares and pre-funded warrants for 958,327 additional shares. Based on 37,423,917 shares outstanding as of July 28, 2026 plus warrant shares, the stake equals 9.0%. They report sole voting and dispositive power.
2 min readBiotech stocks moved sharply after clinical and guidance updates. Tenax Therapeutics (TENX) fell nearly 90% after its Phase 3 LEVEL trial of TNX-103 missed primary and key secondary endpoints. AbCellera Biologics (ABCL) rose on Phase 2 results for ABCL635 in menopausal vasomotor symptoms. 10x Genomics (TXG) gained after raising full-year revenue guidance and citing strong early Atera demand.
6 min readTenax Therapeutics (Nasdaq: TENX) shares fell about 90% to $1.38 after it reported Phase III LEVEL trial top-line results for TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not meet the primary endpoint of improving 6-minute walk distance versus placebo, nor a key secondary endpoint on Kansas City Cardiomyopathy Questionnaire symptom score, according to the company.
2 min readTenax reported its Phase III LEVEL trial of oral levosimendan missed the primary endpoint. The six-minute walk improvement versus placebo was 3.5 meters but not statistically significant, and the quality-of-life endpoint also failed. Subgroup and biomarker results suggested larger benefits in higher-risk patients. Tenax will consult the FDA and EMA and may adjust LEVEL-2 or run a new study.
2 min readUS equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.
7 min readU.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.
7 min readTenax Therapeutics (TENX) shares fell about 84% pre-open after its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) failed to meet the primary endpoint for pulmonary hypertension due to heart failure with preserved ejection fraction, with a 3.5-meter least-squares mean difference and p-value 0.63. It also missed a key secondary endpoint. The company is evaluating next steps and has $118 million cash runway through mid-2028.
4 min readReuters reports that Tenax Therapeutics’ Phase 3 Level trial did not meet its primary endpoint. The article provides no additional trial results or financial guidance. The outcome may affect investor expectations for the company’s lead program and future development plans.
1 min readTENAX THERAPEUTICS, INC. (TENX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE N
4 min readTenax Therapeutics (Nasdaq: TENX) said it granted inducement non-qualified stock options on July 1, 2026 to three newly hired non-executive employees under Nasdaq Rule 5635(c)(4). The awards total 160,000 shares at an exercise price equal to the Nasdaq closing price on grant date, with 25% vesting after one year and the rest monthly over 36 months.
2 min read
